Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

Figure 1

Kaplan-Meier plots of TTF and OS in all patients treated with high-dose treatment in relation to the CYP2C19 (A) and CYP2D6 (B) polymorphisms. The numbers at risk at 0, 24, 48, 72 and 96 months are presented below the figure. A: The green line represents extensive metabolizers (EM) and the blue line represents intermediate metabolizers (IM) and poor metabolizers (PM). B: The green line represents EM and ultra rapid metabolizers (UM) and the blue line represents patients with IM and PM status.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us